Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harbin Pharmaceutical Group CoSHSE:600664 -2.50%56 Debt-to-EBITDA is 1.02 as of Jun. 2026, which is 1% below its 10-year median of 1.03. GuruFocus rates SHSE:600664 with a GF Score™ of 56/100 and a GF Value™ of ¥3.66 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 676 Drug Manufacturers companies, Harbin Pharmaceutical Group Co ranks worse than 51.18% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Harbin Pharmaceutical Group Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:600664'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.88 Med: 1.03 Max: 2.18
Current: 1.71
During the past 13 years, the highest Debt-to-EBITDA Ratio of Harbin Pharmaceutical Group Co was 2.18. The lowest was -4.88. And the median was 1.03.
SHSE:600664's Debt-to-EBITDA is ranked worse than 51.18% of 676
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SHSE:600664: 1.71
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Harbin Pharmaceutical Group Co Debt-to-EBITDA Related Terms
Harbin Pharmaceutical Group Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harbin Pharmaceutical Group Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Harbin Pharmaceutical Group Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Harbin Pharmaceutical Group Co (SHSE:600664) has a Debt-to-EBITDA of 1.02 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Harbin Pharmaceutical Group Co. This is near median its historical median of 1.03. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #346 out of 676 companies in the Drug Manufacturers industry, placing it in the top 51.2%.
Is Harbin Pharmaceutical Group Co's Debt-to-EBITDA too high?
Harbin Pharmaceutical Group Co's current Debt-to-EBITDA of 1.02 is near median its 10-year median of 1.03. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Harbin Pharmaceutical Group Co's value of 1.02 is 37.8% below this industry median. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #346 out of 676 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #346 out of 676 companies for Debt-to-EBITDA. This places Harbin Pharmaceutical Group Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Harbin Pharmaceutical Group Co's value of 1.02 is 37.8% below this benchmark. While the company's 10-year median is 1.03 vs. the industry median of 1.64, Harbin Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 676 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harbin Pharmaceutical Group Co's current Debt-to-EBITDA of 1.02 is 37.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Harbin Pharmaceutical Group Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current Debt-to-EBITDA is 1.02, which is near median its own 10-year median of 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.66, compared to a current price of ¥7.80 — trading 113.1% above its estimated fair value. The current Debt-to-EBITDA is 1.02, which is near median its 10-year median of 1.03 and 37.8% below the Drug Manufacturers industry median of 1.64. Harbin Pharmaceutical Group Co's overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Debt-to-EBITDA is 1.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥7.80 is trading 113.1% above its estimated GF Value™ of ¥3.66.
GuruFocus considers Harbin Pharmaceutical Group Co to be Significantly Overvalued.
Key valuation signals for SHSE:600664:
Debt-to-EBITDA: 1.02 (near median its 10-year median of 1.03)
GF Value™: ¥3.66 vs. price of ¥7.80 (113.1% above fair value)
Industry Position: 37.8% below the Drug Manufacturers median (#346 of 676)
No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
56GF Score
Get the complete analysis for SHSE:600664
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600664 has been successfully added to your 
